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Clinical transplantation tolerance: The promise and challenges.
Organ transplantation is now well established as a preferred
option for the treatment of end-stage organ failure. However,
there is a severe shortage of donor organs and continued loss of
a significant number of organ grafts due to chronic allograft dys-
function. Induction of tolerance of a transplant recipient toward
their foreign organ graft, therefore, remains the “Holy Grail”
of transplantation immunobiologists. Recently, clinical trials to
explore pilot tolerance protocols in humans have been initi-
ated. Defining the ideal strategy(ies) and the role of immuno-
suppressive drugs, developing tolerance assay(s), and enhanc-
ing cooperation between transplant professionals, industry, and
the government are some of the challenges to achieving clinical
transplantation tolerance. This article reviews the promise and
the challenges of achieving clinical transplantation tolerance in
human organ transplant recipients.
Over the last two decades there has been a progressive
improvement of allograft survival, in particular kidney al-
lografts [1]. Intriguingly, this improvement was seen only
in recipients who never had an acute rejection episode,
emphasizing the recipient’s alloimmune response as a
major determinant of overall outcome of the transplant.
Furthermore, the increasing demand of organs for trans-
plantation [2] creates an urgent need for optimizing the
outcome of transplantation by achieving long-term, drug-
free, graft acceptance with normal organ function. The
baffling array of potential complex treatment combina-
tions currently available to the transplant immunobiol-
ogists [3] and the vast experimental data, on ways to
achieve transplantation tolerance, that has amassed since
the original description, half a century ago, of the phe-
nomenon of tolerance in experimental animals implores
us to evaluate where we stand on the road to achiev-
ing clinical transplant tolerance, and underscore the chal-
lenges that we face, so that we may choose the best course
of action [4].
T cells are the vital elements of the immune response
and interact with the alloantigen by the direct and indirect
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pathways, recognizing the foreign major histocompati-
bility complex (MHC) molecules directly on the donor
antigen-presenting cells and processed donor antigens
on self antigen-presenting cells, respectively [5]. The T
cells reacting to their specific antigen can undergo a num-
ber of different responses, namely activation followed by
proliferation and differentiation into effector and mem-
ory cells, and termination. Physiologic termination of the
T-cell immune response is carried out by a number of
mechanisms, specifically, deletion (central or peripheral);
anergy, where T cells are unresponsive to restimulation
with specific antigen; and regulation by regulatory cells
and cytokines [6]. These physiologic mechanisms form
the basis of inducing donor-specific tolerance in clini-
cal transplantation [7–9]. Another possible mechanism
of immunologic tolerance that is unique to the transplant
setting is microchimerism, the persistence of a small num-
ber of donor-derived bone marrow cells in recipients [10–
12].
It is imperative to define transplant tolerance at the
outset so that we understand precisely our objective.
Transplant tolerance does not mean complete unrespon-
siveness of the immune system toward the graft, rather a
lack of a destructive immune response toward it, in the
presence of generalized immune competence [13]. An
operational definition of transplant tolerance in the clin-
ical setting is the absence of acute and chronic rejection
and indefinite graft survival with normal graft function
in an immunocompetent host. The issue of ongoing im-
munosuppression remains to be resolved as to whether
we should aim for a complete drug-free state or, more re-
alistically, accept a minimal amount of ongoing immuno-
suppression/immunomodulation [14].
Generally, reports claiming tolerance induction cite
graft survival in rodents of over 100 days with donor-
specific hyporesponsiveness (indicated by acceptance of
a second graft from the original donor strain and rejec-
tion of third-party grafts). It is impractical to confirm tol-
erance induction in this way, in humans, leaving a void
in this crucial area. Consequently, devising an assay that
allows us to prospectively follow the status of the im-
mune response toward the graft and detect tolerance or
early signs of rejection is an urgent necessity [15–18].
Yet, it seems unlikely that a single assay will provide an
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Table 1. Potential tolerance assays [4]
Measuring T-cell alloreactivity
Proliferation (MLR)
Cytotoxicity (CML)
Cytokine analyses (ELISA, ELISPOT, flow cytometry)
Cell division (CFSE labeling)
Delayed-type hypersensitivity (trans-vivo DTH assay)
Humoral immune response
Alloantibody titers
Profiling of immune cells
Lymphocyte activation markers by flow cytometry
Blood, urine, graft infiltrating cells
“Landscaping” of blood T lymphocytes using transcriptome
technology
Patterns of V-b usage associated with tolerance
(“TCR signature” of tolerance)
Profiling circulating DC subsets
Precursor (p)DC1 and pDC2
Genetic analyses
Immune gene polymorphisms
Defining “tolerance genes” by GeneChip microarray technology
Other assays
Defining “tolerance proteins” by proteomics technology
Graft morphology and immunohistochemistry
Abbreviations are: MLR, mixed lymphocyte reaction; CML, cell-mediated
lymphocytotoxicity; ELISA, enzyme linked immunosorbent assay; ELISPOT,
enzyme-linked immunospot assay; CFSE, carboxy-fluorescein diacetate
succinimidyl ester; DTH, delayed-type hypersensitivity; DC, dendritic cell; TCR,
T cell receptor.
adequate immunologic profile and a panel of assays may
be required. Hitherto, a number of promising assays have
emerged, but their wider clinical validation is still called
for (Table 1).
Very small minorities of patients, who unwittingly dis-
continue their immunosuppression, provide rare exam-
ples of clinical transplant tolerance [19]. The basis of
this immunosuppression-free tolerant state, however, re-
mains intriguing and merits further study so that we may
learn how this can be achieved reproducibly (if at all pos-
sible). This phenomenon has also been reported in pa-
tients receiving total body irradiation as induction ther-
apy [20, 21] and in those kidney transplant recipients who
had received a previous bone marrow transplant from the
same donor, first reported by our group [22] and more
recently by others in a patient with multiple myeloma
complicated by end stage renal failure [23].
The utilization of bone marrow transplantation in or-
der to induce tolerance through mixed chimerism of the
immune system has been expansively studied in animal
models and to a lesser extent in humans [24]. A ma-
jor challenge that remains, for the induction of lasting
chimerism, is the development of clinically applicable
nonmyeloablative regimens that can be safely used in hu-
man leukocyte antigen (HLA)-mismatched patients [25].
A more novel approach to tolerance induction involves
the use of in vitro conditioned or immature donor den-
dritic cells that have the capacity to induce peripheral
and central tolerance [26, 27]. Gene therapy is another
novel approach [28]. Elucidating the optimal conditions
in non-human primates and clarifying the risks associated
with such approaches are the first hurdles to be overcome
before moving on to clinical trials of these strategies.
Other strategies, utilizing T-cell depleting agents or
costimulatory blockade with or without donor-specific
transfusion, appear to achieve tolerance in a variety of
animal models [7] but not in a true sense of the word
in primate models [29]. In the past several years there
has been great enthusiasm about the potential of trans-
lating strategies targeting the CD28/CTLA-4:B7-1/2 and
the CD40:CD154 T-cell costimulatory pathways to the
clinic [5, 30]. Our understanding of these important
costimulatory pathways and their interaction with each
other and other novel pathways such as ICOS:ICOSL,
CD134:CD134L, CD27:CD70, and PD-1:PD-L1/2 are
still unfolding. These novel pathways appear to play
greater roles under some circumstances [31–36]. Target-
ing of these pathways may however only work when the
alloreactive T-cell repertoire is rendered to a manageable
size with adjunctive depleting or deletional therapies [8].
The new immunosuppressive drug rapamycin may play
such a role by inducing T-cell apoptosis [37]. There re-
mains a challenge, however, of defining how much dele-
tion is enough and how safe it is in humans. Further, the
precise impact of the conventional immunosuppressive
drugs on tolerizing strategies needs to be reevaluated,
since the initial suggestion that certain drugs impair the
generation of tolerance in some models [37, 38] have not
proven founded in others [39, 40].
Another major challenge is the resolution of the re-
lationship of tolerance with chronic allograft dysfunc-
tion. There are conflicting data from experimental models
on the impact of alloantigen-dependent and alloantigen-
independent mechanisms on chronic allograft dysfunc-
tion [41–43]. However, some data indicate that donor-
specific hyporesponsiveness is associated with protection
from chronic rejection in humans [44].
The impact of tolerizing regimens on the risk of in-
fectious complications and likewise the detrimental ef-
fect of previous, ongoing or later infections on the induc-
tion or maintenance of tolerance and also on the course
of infection itself is uncertain. Indeed, certain tolerizing
strategies are ineffective if performed during ongoing
infectious episodes [45] and a recent study sheds more
light on the possible mechanism responsible for this phe-
nomenon, suggesting that individuals harboring virally
induced memory T cells that are crossreactive with donor
alloantigen (a phenomenon termed heterologous immu-
nity) are resistant to tolerance induction [12, 46]. On
the other hand, attempting to use a tolerizing regimen
in the presence of a latent infectious agent may allow
tolerance to develop toward it too. Therefore, it seems
prudent to exclude patients with certain chronic or la-
tent infections (e.g., hepatitis B or C, cytomegalovirus,
Epstein-Barr virus) from initial tolerance trials.
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Table 2. Ongoing clinical trials of protolerogenic therapies under the
auspices of Immune Tolerance Network (ITN) [47, 48]
Transplant Therapy
1 Bone marrow and
kidney for
multiple myeloma
and end-stage
renal failure
Non-myeloablative conditioning regimen
(cyclophosphamide, anti-thymocyte
globulin, and thymic irradiation) for
mixed chimerism and induction of
tolerance
2 Kidney Campath 3 combined with sirolimus and
tapering mycophenolate mofetil
3 Bone marrow and
kidney
Cyclosporine, cyclophosphamide,
MEDI-507, and thymic irradiation
4 Kidney Campath-1H, sirolimus, and short course
of tacrolimus
5 Islet Edmonton protocol of steroid-free
immunosuppression: daclizumab,
sirolimus, and low-dose tacrolimus
6 Islet Campath-1H and sirolimus maintenance
therapy
7 Islet hOKT3c1(Ala-Ala) and sirolimus
monotherapy
The choice of which patient population will be the
first to be enrolled into such trials is a very difficult
one, especially when the clinicians are faced with the
ethical issue of risking possible rejection from a failed
tolerance protocol in an era when 1-year graft survival
rates exceed 90% and few grafts are lost to rejection.
There is added convolution, due to conflict of interest of
pharmaceutical companies manufacturing immunosup-
pressive agents currently used, because such tolerizing
strategies may not benefit them. An altruistic coopera-
tion between the biotechnology industry and the trans-
plant biologist is needed to successfully achieve the nec-
essary development of the appropriate tolerizing agents.
Finally, the proper conduct and execution of the clini-
cal trials cannot be overemphasized and will need to be
overseen by a suitably appointed regulatory (governmen-
tal) agency. The Immune Tolerance Network (ITN), NIH
(USA) (http://www.immunetolerance.org) was expressly
instituted for this sole purpose. It provides a platform for
sharing of ideas as well as core facilities and provides a
focus for the development of the most suitable strate-
gies. The ITN is sponsoring several research projects in-
volving islet transplantation, solid organ transplantation
(Table 2) [47], autoimmune disease, allergy/asthma, toler-
ance assay studies and special projects such as “The ITN
Tolerant Kidney Transplant Patient Registry,” to estab-
lish a world-wide registry of kidney transplant recipients
who are off all immunosuppression.
CONCLUSION
We have learned that the goal of clinical transplant tol-
erance is achievable especially in animal models but also
in a few humans. Identifying the most successful of these
strategies and then translating them to larger animals to
test their suitability for the patients is the next step. This
demands persistence and meticulous investigation to con-
firm the robustness and longevity as well as safety of the
tolerance inducing regimens. If we are successful in do-
ing this, then we may still arrive at our chosen destination,
although it may seem very distant.
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